• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research

EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research

Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.
Source: Value in Health - July 24, 2018 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Osama Y. Alshogran, Kenneth J. Smith Source Type: research

Cost-Effectiveness of Edoxaban In Patients With Non-Valvular Atrial Fibrillation In Hong Kong
Atrial fibrillation (AF) is a common arrhythmia associated with debilitating consequences such as stroke, heart failure and venous thromboembolism. In HK, 20-25% of stroke cases are related to AF leading to a significant burden. Warfarin has been the frontline oral anticoagulant for AF but with high bleeding risk and hence monitoring and dose adjustment are required. The non-vitamin-K antagonist oral anticoagulants (NOACs) are alternatives to warfarin for preventing stroke and systemic embolism in non-valvular AF (NVAF) patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: DB Wu, WY Choon, KK Lee Source Type: research

Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research

Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research

Resource Utilisation And Bleeding Events During Anticoagulation Treatment: Real-World Findings From England
This study aimed to estimate the association between healthcare resource use and subsequent bleeding in NVAF patients prescribed VKA in England.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Lister, C Lefevre, I Menown, R Alikhan, L Lacoin, A Bird, M You, E Ridha, D Evans Source Type: research

Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability as worse than death. Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, but is associated with increased bleeding risk and lower quality of life (QoL). Left atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients. This analysis sought to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular AF from the perspective of the US Centers ...
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Reddy, R. Akehurst, S.L. Amorosi, S. Armstrong, S. Beard, C. Knight, C. Taggart, D. Holmes Source Type: research

Relation Of The Time In Therapeutic Range (Ttr) Of Warfarin To Bleeding Incidences In Patients With Atrial Fibrillation
This study aims to compare and establish relation of time in therapeutic range (TTR) of warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereafter of anticoagulation therapy.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M.A.S. Jasmi, M.N. Mazlan, S. Shaharuddin, H.H. Zulkifly, C.M. Long, R. Hashim, Wahab M.S. Abdul Source Type: research